OncoCyte Corp
NASDAQ:OCX

Watchlist Manager
OncoCyte Corp Logo
OncoCyte Corp
NASDAQ:OCX
Watchlist
Price: 2.19 USD -0.9% Market Closed
Market Cap: 36.9m USD
Have any thoughts about
OncoCyte Corp?
Write Note

Relative Value

The Relative Value of one OCX stock under the Base Case scenario is 3.05 USD. Compared to the current market price of 2.19 USD, OncoCyte Corp is Undervalued by 28%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

OCX Relative Value
Base Case
3.05 USD
Undervaluation 28%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
58
vs Industry
26
Median 3Y
53.2
Median 5Y
105.3
Industry
7.6
Forward
73
vs History
vs Industry
Median 3Y
-1.5
Median 5Y
-4.7
Industry
22.1
Forward
-0.8
vs History
vs Industry
Median 3Y
-2.9
Median 5Y
-8.5
Industry
21.9
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-7.6
Industry
23.4
vs History
55
vs Industry
36
Median 3Y
2.9
Median 5Y
5.9
Industry
2.5
vs History
55
vs Industry
24
Median 3Y
47
Median 5Y
91.2
Industry
7.5
Forward
67.7
vs History
vs Industry
8
Median 3Y
79.1
Median 5Y
-501.5
Industry
9.3
vs History
vs Industry
16
Median 3Y
-1.2
Median 5Y
-9.6
Industry
4.2
Forward
-4.7
vs History
vs Industry
13
Median 3Y
-1.2
Median 5Y
-8.8
Industry
4
Forward
-1.1
vs History
vs Industry
33
Median 3Y
-2.4
Median 5Y
-7.9
Industry
5.9
vs History
vs Industry
29
Median 3Y
-2.3
Median 5Y
-7.4
Industry
3.9
vs History
88
vs Industry
64
Median 3Y
0.9
Median 5Y
2.6
Industry
4.5

Multiples Across Competitors

OCX Competitors Multiples
OncoCyte Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
OncoCyte Corp
NASDAQ:OCX
36.9m USD 52 -0.8 -0.8 -0.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 027 714.7 -180 740.1 -219 476 -216 971.5
US
Abbvie Inc
NYSE:ABBV
310.3B USD 5.6 61.1 15.2 23.4
US
Amgen Inc
NASDAQ:AMGN
141.6B USD 4.4 33.5 16 30.4
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD 4.1 915.4 10.2 10.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD 9.6 -213.4 21 22.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 852.6 -472.7 -514.8 -501.1
AU
CSL Ltd
ASX:CSL
134.4B AUD 5.7 31.8 19.7 24.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD 5.6 16.6 15.1 16.7
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.7 -58.8 -53
NL
argenx SE
XBRU:ARGX
35.7B EUR 19.2 -134.7 -108.7 -79.2
P/S Multiple
Revenue Growth P/S to Growth
US
OncoCyte Corp
NASDAQ:OCX
Average P/S: 3 457 244.7
52
283%
0.2
FR
Pharnext SCA
OTC:PNEXF
38 027 714.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.6
20%
0.3
US
Amgen Inc
NASDAQ:AMGN
4.4
26%
0.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.1
10%
0.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
34%
0.3
US
E
Epizyme Inc
F:EPE
1 852.6
N/A N/A
AU
CSL Ltd
ASX:CSL
5.7
23%
0.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
23%
0.2
US
S
Seagen Inc
F:SGT
17.8
118%
0.2
NL
argenx SE
XBRU:ARGX
19.2
220%
0.1
P/E Multiple
Earnings Growth P/E to Growth
US
OncoCyte Corp
NASDAQ:OCX
Average P/E: 211.7
Negative Multiple: -0.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 740.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
61.1
413%
0.1
US
Amgen Inc
NASDAQ:AMGN
33.5
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
915.4
77%
11.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -213.4
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472.7 N/A N/A
AU
CSL Ltd
ASX:CSL
31.8
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -134.7 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
OncoCyte Corp
NASDAQ:OCX
Average EV/EBITDA: 16.2
Negative Multiple: -0.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 476 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.2
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.8 N/A N/A
AU
CSL Ltd
ASX:CSL
19.7
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.1
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -108.7 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
OncoCyte Corp
NASDAQ:OCX
Average EV/EBIT: 21.2
Negative Multiple: -0.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 971.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.4
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.1
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -501.1 N/A N/A
AU
CSL Ltd
ASX:CSL
24.6
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.7
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -79.2 N/A N/A

See Also

Discover More
Back to Top